REGISTER FOR THE 2024 CONFERENCE
Shopping Cart

No products in the cart.

Cancer-associatedcachexia

Tumour-induced alterations in single-nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism.

Tumour-induced skeletal muscle wasting in the context of cancer cachexia is a condition with profound implications for patient survival. The loss of muscle mass is a significant clinical obstacle and is linked to reduced tolerance to chemotherapy and increased frailty....

๐Ÿ—“๏ธ 2024-07-13
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTumour-induced alterations in single-nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism.

Dose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis.

There is inconsistent evidence relating to the effects of megestrol acetate (MA) supplementation on cancer patients suffering from anorexia-cachexia syndrome. This review aimed to examine the dose-response effect of MA supplementation in patients with cancer-associated anorexia/cachexia. Relevant keywords were searched...

๐Ÿ—“๏ธ 2024-06-20
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis.

Hepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis.

Patients with pancreatic ductal adenocarcinoma (PDAC) often suffer from cachexia, a wasting syndrome that significantly reduces both quality of life and survival. Although advanced cachexia is associated with inflammatory signalling and elevated muscle catabolism, the early events driving wasting are...

๐Ÿ—“๏ธ 2024-04-17
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreHepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis.

Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series.

Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most commonly selected measures or their...

๐Ÿ—“๏ธ 2024-05-13
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBody weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series.

Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-naรฏve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received...

๐Ÿ—“๏ธ 2024-09-17
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFrequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

IL36G-producing neutrophil-like monocytes promote cachexia in cancer.

Most patients with advanced cancer develop cachexia, a multifactorial syndrome characterized by progressive skeletal muscle wasting. Despite its catastrophic impact on survival, the critical mediators responsible for cancer cachexia development remain poorly defined. Here, we show that a distinct subset...

๐Ÿ—“๏ธ 2024-09-12
๐Ÿ“ฐ Publication: Nature Communications
Read MoreIL36G-producing neutrophil-like monocytes promote cachexia in cancer.

Ponsegromab for the Treatment of Cancer Cachexia.

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving...

๐Ÿ—“๏ธ 2024-09-14
๐Ÿ“ฐ Publication: New England Journal Of Medicine
Read MorePonsegromab for the Treatment of Cancer Cachexia.

Immunomodulation: A new approach to cancer cachexia, potentially suitable for aging.

Cancer cachexia is the prototypical example of comorbidity, occurring in most of cancer patients. It is a direct consequence of tumor growth and of the associated inflammatory/immune response. Cachexia can be exacerbated by anti-cancer therapies, frequently resulting in dose limitation...

๐Ÿ—“๏ธ 2024-09-10
๐Ÿ“ฐ Publication: Molecular Aspects Of Medicine
Read MoreImmunomodulation: A new approach to cancer cachexia, potentially suitable for aging.

Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

For many patients, the cancer continuum includes a syndrome known as cancer-associated cachexia (CAC), which encompasses the unintended loss of body weight and muscle mass, and is often associated with fat loss, decreased appetite, lower tolerance and poorer response to...

๐Ÿ—“๏ธ 2024-06-27
Read MoreDefining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.

Skeletal Muscle Proteome Modifications following Antibiotic-Induced Microbial Disturbances in Cancer Cachexia.

Cancer cachexia is an involuntary loss of body weight, mostly of skeletal muscle. Previous research favors the existence of a microbiota-muscle crosstalk, so the aim of the study was to evaluate the impact of microbiota alterations induced by antibiotics on...

๐Ÿ—“๏ธ 2024-06-19
๐Ÿ“ฐ Publication: Journal Of Proteome Research
Read MoreSkeletal Muscle Proteome Modifications following Antibiotic-Induced Microbial Disturbances in Cancer Cachexia.

Targeted nutritional intervention attenuates experimental lung cancer cachexia.

Cachexia, a syndrome with high prevalence in non-small cell lung cancer patients, impairs quality of life and reduces tolerance and responsiveness to cancer therapy resulting in decreased survival. Optimal nutritional care is pivotal in the treatment of cachexia and a...

๐Ÿ—“๏ธ 2024-07-04
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeted nutritional intervention attenuates experimental lung cancer cachexia.

KLF10: a point of convergence in cancer cachexia.

Cancer-associated cachexia is a wasting syndrome entailing loss in body mass and a shortened life expectancy. There is currently no effective treatment to abrogate this syndrome, which leads to 20-30% of deaths in patients with cancer. While there have been...

๐Ÿ—“๏ธ 2024-07-15
๐Ÿ“ฐ Publication: Current Opinion In Supportive And Palliative Care
Read MoreKLF10: a point of convergence in cancer cachexia.

The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

With limited treatment options, cachexia remains a major challenge for patients with cancer. Characterizing the interplay between tumor cells and the immune microenvironment may help identify potential therapeutic targets for cancer cachexia. Herein, we investigate the critical role of macrophages...

๐Ÿ—“๏ธ 2024-03-29
๐Ÿ“ฐ Publication: Cancer Cell
Read MoreThe crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

Polymorphism (rs1143634) and IL-1ฮฒ Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients.

Multiple myeloma (MM) is a hematological neoplasm of the early precursor of B-cells. The most characteristic symptoms observed during MM include hypocalcemia, anemia, bacterial infections, and renal damage. Nutritional disorders, especially malnutrition, are noted in about 35-71% of MM patients....

๐Ÿ—“๏ธ 2024-03-24
Read MorePolymorphism (rs1143634) and IL-1ฮฒ Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!